AstraZeneca said on Tuesday its experimental drug baxdrostat significantly lowered blood pressure during a 24-hour window of monitoring in a late-stage trial of patients with treatment-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback